MEP8009A - Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors - Google Patents

Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors

Info

Publication number
MEP8009A
MEP8009A MEP-80/09A MEP8009A MEP8009A ME P8009 A MEP8009 A ME P8009A ME P8009 A MEP8009 A ME P8009A ME P8009 A MEP8009 A ME P8009A
Authority
ME
Montenegro
Prior art keywords
inhibitors
compounds
pyrido
phosphoinosit
synthesis
Prior art date
Application number
MEP-80/09A
Other languages
Bosnian (bs)
English (en)
Inventor
Hengmiao Cheng
Dilip Bhumralkar
Klaus Ruprecht Dress
Jacqui Elizabeth Hoffman
Mary Catherine Johnson
Robert Steven Kania
Phuong Thi Quy Le
Mitchell David Nambu
Mason Alan Pairish
Michael Bruno Plewe
Khanh Tuan Tran
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of MEP8009A publication Critical patent/MEP8009A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
MEP-80/09A 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors MEP8009A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84506506P 2006-09-15 2006-09-15
US94785207P 2007-07-03 2007-07-03
US95262807P 2007-07-30 2007-07-30
PCT/IB2007/002578 WO2008032162A1 (en) 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors

Publications (1)

Publication Number Publication Date
MEP8009A true MEP8009A (en) 2011-12-20

Family

ID=38859750

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-80/09A MEP8009A (en) 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors

Country Status (42)

Country Link
US (3) US7696213B2 (ja)
EP (1) EP2074122B9 (ja)
JP (1) JP4718637B2 (ja)
KR (1) KR101099926B1 (ja)
CN (1) CN101573358B (ja)
AP (1) AP2710A (ja)
AR (1) AR062785A1 (ja)
AT (1) ATE514695T1 (ja)
AU (1) AU2007297212B8 (ja)
BR (1) BRPI0716749B8 (ja)
CA (1) CA2663401C (ja)
CL (1) CL2007002682A1 (ja)
CR (1) CR10662A (ja)
CU (1) CU23783B7 (ja)
CY (1) CY1111911T1 (ja)
DK (1) DK2074122T5 (ja)
DO (1) DOP2009000039A (ja)
EA (1) EA016388B1 (ja)
ES (1) ES2366489T3 (ja)
GE (1) GEP20115306B (ja)
GT (1) GT200700077A (ja)
HK (1) HK1138589A1 (ja)
HN (1) HN2007000267A (ja)
HR (1) HRP20110621T2 (ja)
IL (1) IL197243A (ja)
MA (1) MA30709B1 (ja)
ME (1) MEP8009A (ja)
MX (1) MX2009002927A (ja)
MY (1) MY146420A (ja)
NI (1) NI200900032A (ja)
NO (1) NO342357B1 (ja)
NZ (1) NZ575167A (ja)
PE (1) PE20080670A1 (ja)
PL (1) PL2074122T3 (ja)
PT (1) PT2074122E (ja)
RS (2) RS20090104A (ja)
SI (1) SI2074122T1 (ja)
TN (1) TN2009000085A1 (ja)
TW (1) TWI334353B (ja)
UY (1) UY30588A1 (ja)
WO (1) WO2008032162A1 (ja)
ZA (1) ZA200901477B (ja)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4718637B2 (ja) 2006-09-15 2011-07-06 ファイザー・プロダクツ・インク ピリド（２，３−ｄ）ピリミジノン化合物およびｐｉ３阻害剤としてのその使用
EA020022B1 (ru) * 2007-04-10 2014-08-29 Экселиксис, Инк. Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k-альфа
JP2010523681A (ja) * 2007-04-11 2010-07-15 エクセリクシス， インク． 癌の治療のためのＰＩ３Ｋ−αの阻害剤としてのピリド［２，３−Ｄ］ピリミジン−７−オン化合物
MX336723B (es) * 2008-07-11 2016-01-28 Novartis Ag Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek.
CA2734489C (en) 2008-08-20 2016-11-08 Southern Research Institute Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2326627A1 (en) 2008-08-20 2011-06-01 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AR072940A1 (es) 2008-08-20 2010-09-29 Schering Corp Derivados de piridina y pirimidina sustituidos con etinilo y su uso en el tratamiento de infecciones virales
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8101622B2 (en) * 2008-09-30 2012-01-24 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα and mTOR
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
SG190890A1 (en) 2010-12-16 2013-07-31 Hoffmann La Roche Tricyclic pi3k inhibitor compounds and methods of use
US8664230B2 (en) * 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
WO2013066483A1 (en) 2011-08-31 2013-05-10 Novartis Ag Synergistic combinations of pi3k- and mek-inhibitors
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
JP6631616B2 (ja) 2014-07-26 2020-01-15 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
KR20170058432A (ko) 2014-10-10 2017-05-26 화이자 인코포레이티드 상승 효과적 아우리스타틴 조합
SI3302565T1 (sl) 2015-06-04 2020-02-28 Pfizer Inc. Trdne farmacevtske oblike palbocikliba
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
EP3481822B1 (en) 2016-07-06 2022-06-22 The Regents of The University of Michigan Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
EP3497103B1 (en) 2016-08-15 2021-05-05 Pfizer Inc. Pyridopyrimdinone cdk2/4/6 inhibitors
AU2017376766A1 (en) * 2016-12-14 2019-06-06 Tva (Abc), Llc HSP90-targeting conjugates and formulations thereof
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
IL279329B1 (en) 2018-06-15 2024-09-01 Navitor Pharm Inc Rapamycin analogs and their uses
EP3902801A4 (en) * 2018-12-28 2022-12-14 SPV Therapeutics Inc. CYCLINE-DEPENDENT KINASE INHIBITORS
US20220220103A1 (en) * 2018-12-28 2022-07-14 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
US11819476B2 (en) 2019-12-05 2023-11-21 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
WO2021139775A1 (zh) * 2020-01-10 2021-07-15 江苏先声药业有限公司 吡啶酮化合物及应用
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
KR20230121758A (ko) 2020-11-18 2023-08-21 데시페라 파마슈티칼스, 엘엘씨. Gcn2 및 perk 키나제 억제제 및 그의 사용 방법
CA3238551A1 (en) * 2021-11-18 2023-05-25 Steven FRUCHTMAN Methods and compositions for treating cancer

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
MD1861G2 (ro) 1994-11-14 2002-09-30 Уорнер-Ламберт Кампэни Derivaţi ai 6-arilpirido[2,3-d]pirimidinelor şi naftiridinelor, compoziţie farmaceutică pe baza lor, metode de tratament şi de inhibare a proliferării şi migraţiei celulei receptorului tirozinkinazei
CN1177960A (zh) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en) 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
WO1998033798A2 (en) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9904932D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
SK10772002A3 (sk) 2000-01-27 2004-01-08 Warner-Lambert Company Pyridopyrimidinónové deriváty na liečbu neurodegeneratívnych ochorení
AP2002002643A0 (en) 2000-03-06 2002-12-31 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
ES2360933T3 (es) 2000-04-27 2011-06-10 Astellas Pharma Inc. Derivados de heteroarilo condensados.
EP1364950A4 (en) 2001-02-26 2005-03-09 Tanabe Seiyaku Co PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
GEP20063909B (en) 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
BR0309053A (pt) 2002-04-19 2005-02-22 Smithkline Beecham Corp Compostos
KR20050006221A (ko) 2002-05-06 2005-01-15 제네랩스 테크놀로지스, 인코포레이티드 Ｃ형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換６，６−ヘテロ二環式誘導体
US20050009849A1 (en) 2003-01-03 2005-01-13 Veach Darren R. Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en) 2003-04-02 2004-10-21 Imclone Systems Incorporated 4-fluoroquinolone derivatives and their use as kinase inhibitors
WO2005040337A2 (en) 2003-05-20 2005-05-06 The Regents Of The University Of California METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUES
ATE412650T1 (de) 2003-07-11 2008-11-15 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
US7326788B2 (en) 2003-07-22 2008-02-05 Janssen Pharmaceutica N.V. Quinolinone derivatives as inhibitors of c-fms kinase
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
CN1918158B (zh) 2004-02-14 2011-03-02 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
WO2005082903A1 (en) 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
WO2005094830A1 (en) 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
EP1749004B1 (en) * 2004-05-04 2007-09-19 Warner-Lambert Company LLC Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents
EP1761281A1 (en) 2004-06-04 2007-03-14 Pfizer Products Incorporated Method for treating abnormal cell growth
JP2008510770A (ja) 2004-08-26 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｌｋ阻害剤としての新規プテリジノン
WO2006050501A2 (en) 2004-11-03 2006-05-11 University Of Kansas Novobiocin analogues as anticancer agents
CA2590294A1 (en) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US20060142312A1 (en) 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
EP1940839B1 (en) * 2005-10-07 2013-07-31 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
AU2006302148B2 (en) * 2005-10-07 2012-12-06 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kalpha
EP1872922A1 (en) * 2006-06-27 2008-01-02 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Method and apparatus for manufacturing a polymeric article
AU2007284562B2 (en) 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
JP4718637B2 (ja) 2006-09-15 2011-07-06 ファイザー・プロダクツ・インク ピリド（２，３−ｄ）ピリミジノン化合物およびｐｉ３阻害剤としてのその使用
BRPI0808772A2 (pt) * 2007-03-14 2014-08-12 Exelixis Inc Inibidores da via de hedgehog
JP2010523681A (ja) 2007-04-11 2010-07-15 エクセリクシス， インク． 癌の治療のためのＰＩ３Ｋ−αの阻害剤としてのピリド［２，３−Ｄ］ピリミジン−７−オン化合物
US8101622B2 (en) 2008-09-30 2012-01-24 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα and mTOR
CN102970868A (zh) * 2010-04-16 2013-03-13 柯瑞斯公司 具有k-ras突变的癌症的治疗

Also Published As

Publication number Publication date
PT2074122E (pt) 2011-08-24
SI2074122T1 (sl) 2011-10-28
EP2074122B1 (en) 2011-06-29
HN2007000267A (es) 2011-02-25
AR062785A1 (es) 2008-12-03
UY30588A1 (es) 2008-05-02
AP2710A (en) 2013-07-30
HRP20110621T1 (en) 2011-09-30
IL197243A (en) 2013-07-31
IL197243A0 (en) 2009-12-24
CA2663401A1 (en) 2008-03-20
BRPI0716749A2 (pt) 2014-02-18
US7696213B2 (en) 2010-04-13
KR20090040389A (ko) 2009-04-23
HRP20110621T2 (hr) 2013-12-06
TW200820972A (en) 2008-05-16
RS51927B (en) 2012-02-29
NO20091141L (no) 2009-03-31
MX2009002927A (es) 2009-03-31
CN101573358B (zh) 2012-05-30
US8633204B2 (en) 2014-01-21
BRPI0716749B8 (pt) 2021-05-25
NZ575167A (en) 2010-10-29
KR101099926B1 (ko) 2011-12-28
AU2007297212B8 (en) 2011-04-28
CN101573358A (zh) 2009-11-04
BRPI0716749B1 (pt) 2020-10-06
ZA200901477B (en) 2010-07-28
US20080090801A1 (en) 2008-04-17
EP2074122B9 (en) 2013-09-11
EP2074122A1 (en) 2009-07-01
AU2007297212A1 (en) 2008-03-20
AU2007297212B2 (en) 2011-04-14
PE20080670A1 (es) 2008-06-14
ATE514695T1 (de) 2011-07-15
US20100137279A1 (en) 2010-06-03
GT200700077A (es) 2009-08-03
WO2008032162A8 (en) 2009-03-26
US8273755B2 (en) 2012-09-25
DK2074122T5 (da) 2014-03-17
GEP20115306B (ja) 2011-10-10
RS20090104A (en) 2010-06-30
DOP2009000039A (es) 2015-12-15
JP4718637B2 (ja) 2011-07-06
MY146420A (en) 2012-08-15
US20120309775A1 (en) 2012-12-06
EA200970207A1 (ru) 2009-08-28
CU20090040A7 (es) 2011-07-11
JP2010503653A (ja) 2010-02-04
CU23783B7 (es) 2012-02-15
ES2366489T3 (es) 2011-10-20
CY1111911T1 (el) 2015-11-04
TN2009000085A1 (fr) 2010-08-19
ES2366489T9 (es) 2013-12-27
WO2008032162A1 (en) 2008-03-20
AP2009004790A0 (en) 2009-04-30
MA30709B1 (fr) 2009-09-01
DK2074122T3 (da) 2011-08-15
EA016388B1 (ru) 2012-04-30
CR10662A (es) 2009-04-17
HK1138589A1 (en) 2010-08-27
CL2007002682A1 (es) 2008-04-04
NO342357B1 (no) 2018-05-14
TWI334353B (en) 2010-12-11
CA2663401C (en) 2011-07-12
NI200900032A (es) 2010-05-14
PL2074122T3 (pl) 2011-10-31

Similar Documents

Publication Publication Date Title
MEP8009A (en) Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
EA201000113A1 (ru) Пиразольные соединения
WO2007105058A8 (en) Pyrazole compounds
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
ME01284B (me) Organska jedinjenja
HRP20090235B1 (hr) Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d
ME01992B (me) Jedinjenje diarilhidantoina
SG171593A1 (en) Inhibitors of c-fms kinase
RS51970B (en) TRICYCLIC UNITS AND THEIR USE AS MODULATORS OF GLUCOCORTICOID RECEPTORS
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
RS54386B1 (en) ANTIVIRAL UNITS
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
NO20071880L (no) Diagnostic Compounds
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
DOP2006000014A (es) Derivados de triazol sustituidos como antagonistas de oxitocina
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
ECSP088925A (es) Nitrilos espirocíclicos como inhibidores de proteasa
PA8792101A1 (es) Nuevo procedimiento de sintesis del ( 7-metoxi-1- naftil) aceto
CR11463A (es) Compuestos de piridilmetil-sulfonamida
NO20085317L (no) Imidazoazepinonforbindelser
EA201100502A1 (ru) Гликозидные производные и их применения
HRP20090011T3 (en) 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidines used as cgrp antagonists
DE602007005387D1 (de) Ptors
DE602004031878D1 (de) Immunhemmende pyrazolon-verbindungen